Sheena C. Tenney

Also affiliated with Children's Oncology Group

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “Outcomes and toxicities in patients (pts) non-randomly assigned to immunotherapy Children’s Oncology Group (COG) ANBL0032.”.

Outcomes and toxicities in patients (pts) non-randomly assigned to immunotherapy Children’s Oncology Group (COG) ANBL0032.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.10523

N/A

0DataRank · unranked

0 citations

Andrew L. Gilman, M. Fevzi Özkaynak, Arlene Naranjo, Wendy B. London, Sheena C. Tenney +11 more

Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-3909

N/A

0DataRank · unranked

216 citations

Andrew L. Gilman, M. Fevzi Özkaynak, Arlene Naranjo, Mitchell B. Diccianni, Jacek Gan +14 more

Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1

Transplantation and Cellular Therapy(2021)10.1016/j.jtct.2021.03.006

N/A

0DataRank · unranked

33 citations

Arlene Naranjo, Rochelle Bagatell, Steven G. DuBois, Jeannine S. McCune, Sheena C. Tenney +17 more

Data from Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032

(2023)10.1158/1078-0432.c.6531294

N/A

0DataRank · unranked

0 citations

Andrew L. Gilman, M. Fevzi Özkaynak, Arlene Naranjo, Mitchell B. Diccianni, Jacek Gan +14 more

Data from Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032

(2023)10.1158/1078-0432.c.6531294.v1

N/A

0DataRank · unranked

0 citations

Andrew L. Gilman, M. Fevzi Özkaynak, Arlene Naranjo, Mitchell B. Diccianni, Jacek Gan +14 more

Outcomes of patients with intermediate‐risk neuroblastoma presenting with motor deficits relating to intraspinal tumor extension: A report from the Children's Oncology Group study ANBL0531

Pediatric Blood & Cancer(2024)10.1002/pbc.31407

N/A

0DataRank · unranked

1 citations

Howard M. Katzenstein, Arlene Naranjo, Sheena C. Tenney, Lulu Chen, Wendy B. London +11 more